LT2556071T - Kinazės inhibitoriai ir jų panaudojimas vėžio gydymui - Google Patents
Kinazės inhibitoriai ir jų panaudojimas vėžio gydymuiInfo
- Publication number
- LT2556071T LT2556071T LTEP11764988.9T LT11764988T LT2556071T LT 2556071 T LT2556071 T LT 2556071T LT 11764988 T LT11764988 T LT 11764988T LT 2556071 T LT2556071 T LT 2556071T
- Authority
- LT
- Lithuania
- Prior art keywords
- treating cancer
- kinase inhibitors
- kinase
- inhibitors
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32132910P | 2010-04-06 | 2010-04-06 | |
| US32133210P | 2010-04-06 | 2010-04-06 | |
| PCT/CA2010/000518 WO2010115279A1 (en) | 2009-04-06 | 2010-04-06 | Kinase inhibitors and method of treating cancer with same |
| PCT/CA2011/000386 WO2011123946A1 (en) | 2010-04-06 | 2011-04-06 | Kinase inhibitors and method of treating cancer with same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2556071T true LT2556071T (lt) | 2017-01-25 |
Family
ID=44761967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP11764988.9T LT2556071T (lt) | 2010-04-06 | 2011-04-06 | Kinazės inhibitoriai ir jų panaudojimas vėžio gydymui |
Country Status (25)
| Country | Link |
|---|---|
| US (9) | US8921545B2 (enExample) |
| EP (2) | EP2556070B1 (enExample) |
| JP (1) | JP5442906B2 (enExample) |
| KR (1) | KR101782668B1 (enExample) |
| CN (1) | CN102892766B (enExample) |
| AU (1) | AU2011238384B2 (enExample) |
| BR (1) | BR112012025496B1 (enExample) |
| CY (1) | CY1118610T1 (enExample) |
| DK (1) | DK2556071T3 (enExample) |
| EA (1) | EA023173B1 (enExample) |
| ES (2) | ES2603613T3 (enExample) |
| HR (1) | HRP20161498T1 (enExample) |
| HU (1) | HUE030651T2 (enExample) |
| IL (1) | IL221556A (enExample) |
| LT (1) | LT2556071T (enExample) |
| ME (1) | ME02545B (enExample) |
| MX (1) | MX2012011516A (enExample) |
| NZ (1) | NZ602350A (enExample) |
| PL (1) | PL2556071T3 (enExample) |
| PT (1) | PT2556071T (enExample) |
| SG (1) | SG183875A1 (enExample) |
| SI (1) | SI2556071T1 (enExample) |
| SM (1) | SMT201600430B (enExample) |
| TW (1) | TWI516262B (enExample) |
| WO (2) | WO2011123946A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011506494A (ja) | 2007-12-21 | 2011-03-03 | ユニバーシティ・ヘルス・ネットワーク | 癌の治療に有用なキナーゼ阻害剤としてのインダゾリル、ベンズイミダゾリル、ベンゾトリアゾリル置換インドルモン誘導体 |
| US8481525B2 (en) | 2009-04-06 | 2013-07-09 | University Of Health Network | Kinase inhibitors and method of treating cancer with same |
| EA023173B1 (ru) * | 2010-04-06 | 2016-04-29 | Юниверсити Хелс Нетворк | Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью |
| US8933070B2 (en) | 2010-07-02 | 2015-01-13 | University Health Network | Methods of targeting PTEN mutant diseases and compositions therefor |
| WO2012048411A1 (en) * | 2010-10-13 | 2012-04-19 | University Health Network | Plk-4 inhibitors and method of treating cancer with same |
| EP3444238B1 (en) * | 2012-07-27 | 2021-12-08 | Sato Pharmaceutical Co., Ltd. | Process for preparing difluoromethylene compounds |
| EP3057593B1 (en) | 2013-10-18 | 2021-12-08 | University Health Network | Treatment for pancreatic cancer |
| KR20160070106A (ko) * | 2013-10-18 | 2016-06-17 | 유니버시티 헬스 네트워크 | Plk-4 억제제의 염 및 결정체들 |
| CN104130175A (zh) * | 2014-06-13 | 2014-11-05 | 天津科技大学 | 不同位置取代吲哚酮类衍生物及其应用 |
| US11608334B2 (en) | 2017-02-08 | 2023-03-21 | The National Institutes of Pharmaceutical R&D Co., Ltd. | Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof |
| CN108947970B (zh) * | 2017-05-18 | 2022-04-05 | 四川大学 | 吲唑类衍生物及其制备方法和用途 |
| AU2018328773B2 (en) | 2017-09-08 | 2023-11-16 | University Health Network | Combination therapies for inhibition of Polo-like Kinase 4 |
| WO2020097400A1 (en) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof |
| US12522583B2 (en) | 2018-11-07 | 2026-01-13 | Dana-Farber Cancer Institute, Inc. | Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof |
| US12415816B2 (en) | 2018-11-07 | 2025-09-16 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| SG11202111003UA (en) | 2019-04-24 | 2021-11-29 | Univ Health Network | Crystal form s4 of the plk4 inhibitor (1r,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6- yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate |
| KR20220124177A (ko) * | 2019-12-06 | 2022-09-13 | 유니버시티 헬스 네트워크 | 급성 골수성 백혈병 또는 골수형성이상증후군의 치료방법 |
| TW202204350A (zh) | 2020-05-06 | 2022-02-01 | 美商雅捷可斯治療公司 | 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑 |
| CN112250614B (zh) | 2020-10-20 | 2022-02-01 | 苏州大学 | 3-螺三元环吲哚酮衍生物的合成方法 |
| US12043632B2 (en) | 2020-12-23 | 2024-07-23 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
| TW202300485A (zh) * | 2021-03-02 | 2023-01-01 | 大陸商上海齊魯製藥研究中心有限公司 | Plk4抑制劑及其用途 |
| CN117794529B (zh) | 2021-05-11 | 2025-02-11 | 欧瑞克制药公司 | Polo样激酶4抑制剂 |
| CN115677682B (zh) * | 2021-07-30 | 2023-07-18 | 上海齐鲁制药研究中心有限公司 | 螺环类plk4抑制剂及其用途 |
| WO2023086320A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of jak2 |
| CA3234638A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| WO2024006379A1 (en) * | 2022-06-30 | 2024-01-04 | Axonis Therapeutics, Inc. | Methods and compounds for inhibiting mkk7 enzymes |
| AU2024249981A1 (en) | 2023-04-06 | 2025-10-16 | Pfizer Inc. | Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3310891A1 (de) | 1983-03-25 | 1984-09-27 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte |
| US5182397A (en) * | 1990-05-31 | 1993-01-26 | American Cyanamid Company | Aryloxyspiroalkylindolinone herbicides |
| GB9507298D0 (en) | 1995-04-07 | 1995-05-31 | Pharmacia Spa | Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| AU4155697A (en) | 1996-08-23 | 1998-03-06 | Sugen, Inc. | Indolinone combinatorial libraries and related products and methods for the treatment of disease |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6133305A (en) * | 1997-09-26 | 2000-10-17 | Sugen, Inc. | 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity |
| AU5468499A (en) | 1998-08-04 | 2000-02-28 | Sugen, Inc. | 3-methylidenyl-2-indolinone modulators of protein kinase |
| AU3770000A (en) | 1999-03-24 | 2000-10-09 | Sugen, Inc. | Indolinone compounds as kinase inhibitors |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| CA2410509A1 (en) | 2000-06-02 | 2001-12-13 | Sugen, Inc. | Indolinone derivatives as protein kinase/phosphatase inhibitors |
| US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| CN1656079A (zh) | 2002-05-31 | 2005-08-17 | 卫材株式会社 | 吡唑化合物和含有该化合物的药物组合物 |
| US7148249B2 (en) | 2002-09-12 | 2006-12-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments |
| WO2004037247A1 (en) * | 2002-10-21 | 2004-05-06 | Irm Llc | Oxindoles with anti-hiv activity |
| WO2005058309A1 (en) | 2003-12-16 | 2005-06-30 | Leo Pharma A/S | Novel therapeutic use of indolinone derivatives |
| US20050211590A1 (en) | 2004-03-26 | 2005-09-29 | Mcclure George K | Protective cover for medical devices |
| DE102005005395A1 (de) | 2005-02-03 | 2006-08-10 | Schering Aktiengesellschaft | Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
| US7309787B2 (en) * | 2005-07-13 | 2007-12-18 | Allergan, Inc. | Kinase inhibitors |
| WO2007058626A1 (en) * | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
| US20070135509A1 (en) | 2005-12-09 | 2007-06-14 | Blackburn Thomas P | Indolone compounds useful to treat cognitive impairment |
| FR2896503B1 (fr) | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| WO2007109026A2 (en) | 2006-03-15 | 2007-09-27 | The Trustees Of Columbia University In The City Of New York | Pten compositions and methods for detecting breast cancer |
| GB0606234D0 (en) | 2006-03-29 | 2006-05-10 | Pliva Istrazivanje I Razvoj D | Pharmaceutically acceptable salts and polymorphic forms |
| JP5551066B2 (ja) * | 2007-06-12 | 2014-07-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化合物 |
| CN103122001A (zh) | 2007-09-25 | 2013-05-29 | 武田药品工业株式会社 | Polo样激酶抑制剂 |
| WO2009065232A1 (en) | 2007-11-20 | 2009-05-28 | University Health Network | Cancer diagnostic and therapeutic methods that target plk4/sak |
| JP2011506494A (ja) * | 2007-12-21 | 2011-03-03 | ユニバーシティ・ヘルス・ネットワーク | 癌の治療に有用なキナーゼ阻害剤としてのインダゾリル、ベンズイミダゾリル、ベンゾトリアゾリル置換インドルモン誘導体 |
| JP2009173629A (ja) * | 2007-12-21 | 2009-08-06 | Banyu Pharmaceut Co Ltd | Ｒｓｋ１阻害作用を有する新規スピロインダン誘導体 |
| CA2717904C (en) * | 2008-03-11 | 2016-08-30 | University Health Network | Method of treating cancer using a neuropeptide y 5r (np y5r) antagonist |
| EP2108641A1 (en) * | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
| EP2113503A1 (en) * | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
| WO2010008731A1 (en) | 2008-06-16 | 2010-01-21 | Tigris Pharmaceuticals, Inc. | Methods for determining sensitivity to aminoflavones |
| DE102008040187A1 (de) | 2008-07-04 | 2010-01-07 | Robert Bosch Gmbh | Sensorelement, Verfahren zu seiner Herstellung sowie Verwendung |
| WO2010017047A1 (en) | 2008-08-05 | 2010-02-11 | Merck & Co., Inc. | Therapeutic compounds |
| US8481525B2 (en) | 2009-04-06 | 2013-07-09 | University Of Health Network | Kinase inhibitors and method of treating cancer with same |
| WO2011069298A1 (en) | 2009-12-11 | 2011-06-16 | F. Hoffmann-La Roche Ag | Novel cyclopropane indolinone derivatives |
| JP5056876B2 (ja) | 2010-03-19 | 2012-10-24 | Ｊｆｅスチール株式会社 | 冷間加工性と焼入れ性に優れた熱延鋼板およびその製造方法 |
| EA023173B1 (ru) | 2010-04-06 | 2016-04-29 | Юниверсити Хелс Нетворк | Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью |
| US8933070B2 (en) | 2010-07-02 | 2015-01-13 | University Health Network | Methods of targeting PTEN mutant diseases and compositions therefor |
| WO2012048411A1 (en) | 2010-10-13 | 2012-04-19 | University Health Network | Plk-4 inhibitors and method of treating cancer with same |
| EA024026B1 (ru) | 2010-11-25 | 2016-08-31 | Рациофарм Гмбх | Новые соли и полиморфные формы афатиниба |
| EP3323820B1 (en) * | 2011-02-28 | 2023-05-10 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| GB201109966D0 (en) | 2011-06-10 | 2011-07-27 | Cancer Res Inst Royal | Materials and methods for treating pten mutated or deficient cancer |
| WO2013053051A1 (en) | 2011-10-12 | 2013-04-18 | University Health Network | Indazole compounds as kinase inhibitors and method of treating cancer with same |
| EP3057593B1 (en) | 2013-10-18 | 2021-12-08 | University Health Network | Treatment for pancreatic cancer |
| KR20160070106A (ko) | 2013-10-18 | 2016-06-17 | 유니버시티 헬스 네트워크 | Plk-4 억제제의 염 및 결정체들 |
-
2011
- 2011-04-06 EA EA201270752A patent/EA023173B1/ru unknown
- 2011-04-06 WO PCT/CA2011/000386 patent/WO2011123946A1/en not_active Ceased
- 2011-04-06 ES ES11764988.9T patent/ES2603613T3/es active Active
- 2011-04-06 HR HRP20161498TT patent/HRP20161498T1/hr unknown
- 2011-04-06 PT PT117649889T patent/PT2556071T/pt unknown
- 2011-04-06 SI SI201131015A patent/SI2556071T1/sl unknown
- 2011-04-06 ES ES11764989T patent/ES2639757T3/es active Active
- 2011-04-06 PL PL11764988T patent/PL2556071T3/pl unknown
- 2011-04-06 TW TW100111767A patent/TWI516262B/zh active
- 2011-04-06 KR KR1020127029064A patent/KR101782668B1/ko active Active
- 2011-04-06 LT LTEP11764988.9T patent/LT2556071T/lt unknown
- 2011-04-06 US US13/639,648 patent/US8921545B2/en active Active
- 2011-04-06 DK DK11764988.9T patent/DK2556071T3/en active
- 2011-04-06 AU AU2011238384A patent/AU2011238384B2/en active Active
- 2011-04-06 US US13/081,254 patent/US8263596B2/en active Active
- 2011-04-06 EP EP11764989.7A patent/EP2556070B1/en active Active
- 2011-04-06 BR BR112012025496-0A patent/BR112012025496B1/pt active IP Right Grant
- 2011-04-06 SG SG2012065090A patent/SG183875A1/en unknown
- 2011-04-06 EP EP11764988.9A patent/EP2556071B1/en active Active
- 2011-04-06 NZ NZ602350A patent/NZ602350A/en unknown
- 2011-04-06 MX MX2012011516A patent/MX2012011516A/es active IP Right Grant
- 2011-04-06 CN CN201180018148.2A patent/CN102892766B/zh active Active
- 2011-04-06 JP JP2013502966A patent/JP5442906B2/ja active Active
- 2011-04-06 ME MEP-2016-265A patent/ME02545B/me unknown
- 2011-04-06 HU HUE11764988A patent/HUE030651T2/en unknown
- 2011-04-06 WO PCT/CA2011/000387 patent/WO2011123947A1/en not_active Ceased
-
2012
- 2012-06-21 US US13/529,542 patent/US8481533B2/en active Active
- 2012-08-21 IL IL221556A patent/IL221556A/en active IP Right Grant
-
2013
- 2013-07-03 US US13/935,021 patent/US9139563B2/en active Active
-
2014
- 2014-12-23 US US14/580,658 patent/US9579327B2/en active Active
-
2015
- 2015-08-11 US US14/823,057 patent/US9907800B2/en active Active
-
2016
- 2016-11-17 CY CY20161101184T patent/CY1118610T1/el unknown
- 2016-11-24 SM SM201600430T patent/SMT201600430B/it unknown
-
2017
- 2017-02-23 US US15/440,548 patent/US9796703B2/en active Active
- 2017-10-23 US US15/790,847 patent/US10077255B2/en active Active
-
2018
- 2018-02-22 US US15/902,143 patent/US10358436B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2556071T3 (pl) | Inhibitory kinaz i ich zastosowanie w leczeniu raka | |
| ZA201300255B (en) | Morpholino pyrimidines and their use in therapy | |
| IL238400A0 (en) | Triazolopyrazines as brd4 inhibitors for use in cancer therapy | |
| IL214626A0 (en) | Prodrug forms of kinase inhibitors and their use in therapy | |
| SG11201404596UA (en) | Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer | |
| ZA201207574B (en) | Phytocannabinoids in the treatment of cancer | |
| ZA201404965B (en) | Inhibitors of notch signalling pathway and use thereof in treatment of cancers | |
| IL228847A0 (en) | il1r1 inhibitors and their use in cancer treatment | |
| IL232353B (en) | An inhibitor of the nedd8 mecatenase and a hypomethylated agent for use in cancer therapy | |
| ZA201204423B (en) | Neuregulin antagonists and use thereof in treating cancer | |
| IL218182A0 (en) | Kinase inhibitors, prodrug forms thereof and their use in therapy | |
| HRP20171280T1 (hr) | Pirazolilgvanidinski inhibitori f1f0-atpaze i njihova upotreba u terapiji | |
| IL202307A0 (en) | Multikinase inhibitors for use in the treatment of cancer | |
| IL233080A0 (en) | Bisarylsulfonamides used to treat inflammation and cancer | |
| EP2537031A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | |
| GB201718726D0 (en) | Phytocannabinoids in the treatment of cancer | |
| SG11201406199TA (en) | Methods for treating cancer using pi3k inhibitor and mek inhibitor | |
| HK1180315A (en) | Kinase inhibitors and their use in treating cancer | |
| IL225959A0 (en) | Methods and preparations for diagnosis and treatment @ בסרטן | |
| EP2632494A4 (en) | METHODS AND COMPOSITIONS FOR EVALUATING AND TREATING CANCER | |
| ZA201105917B (en) | Prodrug forms of kinase inhibitors and their use in therapy | |
| HUP1000688A2 (en) | Use of trifluoro-phthalimides in the treatment of cancer | |
| IL234913A0 (en) | Cancer treatment methods using pi3k inhibitor and mek monitoring |